Voyager Therapeutics, Inc. (VYGR) Free cash flow 2016–2025
Voyager Therapeutics, Inc. (VYGR) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$135.1MFY2025 · since FY2016: -$47.5M → -$135.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$135.1M | -617.2% |
| FY2024 | -$18.8M | -125.2% |
| FY2023 | $74.7M | +597.8% |
| FY2022 | -$15.0M | +72.8% |
| FY2021 | -$55.1M | +49.3% |
| FY2020 | -$108.8M | -365.7% |
| FY2019 | $40.9M | +302.8% |
| FY2018 | -$20.2M | +69.1% |
| FY2017 | -$65.3M | -37.5% |
| FY2016 | -$47.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More VYGR financial trends
VYGR RevenueVYGR Net incomeVYGR Net marginVYGR Gross profitVYGR Gross marginVYGR Operating incomeVYGR Operating marginVYGR Operating cash flowVYGR Capital expendituresVYGR Return on equityVYGR Stock buybacksVYGR Dividends paidVYGR Total assetsVYGR Total liabilitiesVYGR Shareholders’ equityVYGR overview →